¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º }[>RxHd  
[Krm .)  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ z'?7]C2b  
+=ZWau   
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) RNv{n mf  
U6c)"^\  
1. ICAM-1 &Pu+(~'Q  
5nMkd/  
2. interleukin 12(IL-12) l5FuMk-  
B;xZ% M]  
3. tumor infiltrating lymphocyte W<\kf4Y  
Zg)_cRR   
4. TCR/CD3 complex `Mg8]H~  
QuSV&>T\  
5. hematopoietin receptor family ad"'O]  
p&i. )/  
6. individual idiotype(IdI) Ho|o,XvLv  
Wyy^gJ l  
7. integrin lq:]`l,6@  
c:=7lI   
8. colony-stimulatory factor (CSF) 8h*t55  
<_"B}c/2$  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 9Hu d|n  
ypH8QfxLTr  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? *dN N<  
uaiz*Im  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ S"zk!2@C  
E(_ KN[}S  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ(/&;jV2DD[  
7skljw(  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ Z(p*Z,?u  
?{eY\I  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) R<|ejw  
0E-pA3M6  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ \^9pW 2v  
:/6()_>bO  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) RAV^D.  
'99@=3AB:`  
3. immunoglobulin superfamily (IgSF) _ %{0?|=  
bG(x:Py&  
4. selectin 4@6 <  
jJia.#.Ze  
5. anti-idiotypic antibody (¦ÁId) LKx`v90p  
.#0H{mk  
6. major histocompatibility complex(MHC) mZ7B<F[qV  
9 6=Z"  
7. immunotolerance 3 CM^j<9  
1[SA15h  
8. biological reponse modifier(BRM) (9]6bd  
(~&w-w3  
9. immune reponse gene (Ir gene) J=iRul^S  
d; =u  
10. reshaped antibody (or reconstituted antibody) RBE7485  
pDn&V (  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© uE`r/=4  
_R^y\1Qu  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ T@P!L  
>b48>@~bY  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? t'g^W  
JoJukoy}F  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ s8vKKvs`9  
SkHYXe"]  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? #{*LvI&  
E'EcP4eL  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ ar$*a>'?  
=45W\  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? | -+zofx  
]Blf9h7  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 2*2:-o cl$  
L:@fP~Erh  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ opp!0:jS*  
sg AzL  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? +,5-qm)Gh>  
UyiJU~r1  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ u9Y3?j,oC  
%8r/oS  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: .L EY=j!-s  
~OypE4./1  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ;Vu5p#,O<M  
(9C<K<  
ÃâÒßѧ :iPy m}CE  
2k5/SV X  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© } ]6f+  
qCPmbg  
1. CD8 Q(Gl{#b  
GF$`BGW  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) Or0O/\D)  
EWj gI_-  
3. immunoglobulin fold(Ig fold) t ^SzqB  
_Z Y\,_  
4. cadherin (Ca-dependent cell adhesion moleculers) !3 qVB  
e0HfP v_  
5. idiotype-anti-idiotypic antibody immune network theory v)X\GmW7w  
*d*,Hqn  
6. HLA class II antigen _NZ@4+aW  
p/ GVTf  
7. complementarity-determining region (CDR) e'9r"<>i  
"TOa=Tt{,  
8. perforin(or pore-forming protein ,PFP) {XCf-{a]~  
v& $k9)]  
9. high affinity IL-2 receptor ,5Vt]#F5@  
r'7LR  
10. artificial active immunization j2 %^qL  
pY"O9x  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© >SbK.Q@ei  
] d}0l6  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠjeUUa-zR3  
S.*~C0"  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 }hpm O-  
4=8QZf0\  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ {Qu"%h.Al  
yHo[{,4itA  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ $A_]:qI2  
@~td`Z?1 y  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ 5s{j = .O  
SkQswH  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? Dh4 6o|P  
$FTO  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ bC!`@/  
B=f,QU  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ ,MPB/j^o5!  
R\3VB NX.g  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ dq;|?ESP  
OHr Y(I6  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ g`^X#-!(  
&C<yfRDu  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© VSX@e|Nj  
]  ]U<UJ  
1. immunoglobulin gene rearrangement =<@2#E)  
:(|'S4z  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) z+}QZ >  
B<?[Mrdxw  
3. flow cytometry(FCM) .R*!aK  
O)|P,?  
4. carrier effect J@pb[OL,  
sb_oD{+gW  
5. positive selection of T lymphocytes in thymus lH^^77"4Qo  
DhLqhME53  
6. mouse TH1(Th1) and TH2(Th2) subsets \`<cH#  
[D "t~QMr  
7. perforin (pore-forming protein ,PFP) pL=d% m.W  
gF=jf2{YX  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) ^efb 5  
^mWybPqx  
9. SH-2(src-homology region 2) W W2 Ob*  
JCcZuwu[  
10. Ab2¦Â (internal image) YYEJph@06q  
WO4=Mte?  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© c }*2$1  
-4rDbDsr  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? c3*t_!@oC  
,B(7\  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? >h2%[j=  
87%*+n:?*  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ8[CB>-9  
*%w6 9#D  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ Z@8vL  
.x`M<L#M(  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ?&LZB}1 R  
_zt1 9%Wg  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) k%wn0Erd  
I KtB;  
ÃâÒßѧרҵ£º n?\ nn3  
)b<k#(i@#  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ \ \BCcr\l  
F62V 3 Xy  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? y-p70.'{U  
d_n7k g+  
´«È¾²¡Ñ§×¨Òµ£º w{~+EolK  
~^u16z,  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 1Gt/Tq$_b  
I/VxZ8T  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ l no vykR  
*`j-i  
Ïû»¯×¨Òµ£º }?cGf- c  
<9=9b_z  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ /&u<TJ4  
0JgL2ayIVI  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? )!g{Sbl  
hS[ yNwD  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ 2^t#6XBk/  
;})5:\h  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© JKer//ng4  
<<D$+@wxm  
1. Fas(CD95)/FasL c4_`Ew^k  
st"{M\.p  
2. common chain of cytokine receptor _#$ *y  
#j@71]GI  
3 . TCR/CD3 complex 2tROT][J%  
Xtwun  
4. negaive selection of thymocytes =9kN _:-  
?ER-25S  
5. artificial active immune ,!V] jP)  
J$~<V IX  
6. anti-idiotypic BmHwu{n'  
+(uYwdcN  
7. IgSF 0!z@2[Pe66  
p3/*fH98  
8. Integrin $3Z-)m  
DK0.R]&4(  
9. chemokine 0 ugT2%  
IV lf=k  
10. B7/CD28 [~:-&   
i{D=l7j|w  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© jGrN\D?h  
dD<fn9t  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ v^ d]r Sm  
"RVcA",  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ OT^%3:zg  
*5<Sr q'  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ '8Phxx|  
A]L%dFK  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ %+ZJhHT  
m\/ Tj0e  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ a?yMHb{F  
^I KO2Ft  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ  p0.|<  
CIjZG?A  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© )} DUMq7  
oJKa"H-jL  
1. B7/CD28 /v095H@  
A?TBtAe  
2. Th1 subset PX|=(:(k  
EkT."K  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© g~UUP4<$"  
yGg,$WM  
4. antibody affinity maturation I2(zxq&2M\  
d2X [(3  
5. AP-1 nS()u}c;r  
Hn,:`mj4-6  
6. single chain variable fragment£¨ScFv£© tU"raP^ =  
{%w! @-  
7. NK cell receptor Oo?,fw  
D[O{(<9  
8. Zinkernagel-Doherty phenomenon UEak^Mm;=2  
i?Ss:v^  
9. Ig fold > Oh?%%6  
#6Xs.*b5C  
10. CD40/CD40L Qy#)Gxp  
\qi|Js*{  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© qDWsvx]  
S{',QO*D6  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ _<ut) G^9  
NGYyn`Lx  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ \EbbkN:D  
s!/TU {8J  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ ctQbp~-  
3+MB5 T  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ S)He$B$pp  
9^P2I)aD  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£  Do?P<x o  
\^*< y-jL  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ <(@Syv )  
m9M FwfZ  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ X7UBopm&  
mzL[/B#>M  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© ps1YQ3Ep&  
lfk9+)  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© %R_{1GrL'c  
=fc: 6JR  
1.Co-stimulators (or co-stimulating molecules) v4?iOD  
~Y5l+EF#  
2.NK-kB kL@Wb/K JP  
=4C}{IL  
3.Immunoglobulin superfamily Ex@`O+  
a7H0!9^h  
4.antigen-presenting cell (APC) (g/7yO(s  
t[.W$1 =  
5.death domain }|8*sk#[  
g;F"7 ^sg  
6.CCR and CXCR TmEY W<  
k/&]KYwu  
7.Lectin (or mitogen) 5$l9@0D.\  
T)u4S[ &  
8.Clusters of differentiation, CD) f%^'P"R  
Uku5wPS  
9.B7 family 4yV].2#rl"  
eVy2|n9rH  
10.Cytotoxic T lymphocyte, CTL) f|0lj   
3VCqp13  
11.IL-15 and IL-15 receptor (IL-15R) ~2%3FV^  
Hw_o w ?  
12.MHC restriction vd~U@-C=R  
?#[)C=p]z  
13.Affinity-chromatography G\H q/4  
y,C!9l  
14.Cyctosprin A, CsA  0%Q9}l#7  
N_'+B+U?  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) fp !:u  
=3+L#P=i9  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© O8RzUg&  
r#h {$iW  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 MQw9X  
 ]6~k4  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ mZoD033H  
CyTF b$Z  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ `ut)+T V  
_ VKgs]Y  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© E`E'<"{Yd  
*F Pg#a+  
ÃâÒßѧרҵ£º "Pdvmur  
Q]i[.ME  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ $%}>zqD1  
75Fp[Q-  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ Yf (im  
+{vQS FW  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ -Op@y2+c  
-- S"w@  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) GMb!Q0I8  
= o+7xom  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) RK3.-  
1Zq   
1. ADCC(antibody dependent cell-mediated cytotoxicity) lm &^tjx  
R#fy60  
2. »·æß¾úËØ(cyclosporin) &Q+]t"OA!  
Ph"iX'J  
3. KIR(killer cell inhibitory receptor) 8>v7v&Bh|  
% &+|==-  
4. HLDA(human leucocyte differentiation antigen) Xa*?<(^`  
"o<D;lO  
5. Interleukin 18(IL-18) y3 AL)  
5Q;dnC  
6. ÕûºÏËØ(integrin) AG=9b  
XWf7"]%SX  
7. Fas/FasL W9+h0A-  
>+f'!*%7He  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) nYgx9Q"<om  
SE-} XI\  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) LNbx3W oC  
<JJkki  
10. Th1/Th2 TA<hj[-8  
iF+S%aPd#  
11. »ùÒòÒßÃç(DNAÒßÃç) WY3_7k8u  
I}1fEw>8  
12. chemokines and chemokine receptor Jn60i6/  
(kdC1,E  
13. ÃâÒßÄÍÊÜ 0yKwH\S  
+-'`Q Ae  
14. ¹²´Ì¼¤·Ö×Ó 37,L**Dgs  
c;nx59w ]q  
15. ËÀÍö½á¹¹Óò(death domain) pEJ#ad  
fWqv3nY^  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) b^+Fs  
 aKa  R  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? P~n8EO1r  
#I bS  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠBd/} %4V\@  
VM=hQYe  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î zK[ 7:<  
fpI; `s  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ Sa( yjF1  
X!7 c zt  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå TB ;3`  
.G7]&5s  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ \Ac}R'  
K'a#Mg  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) bS_y_ 9K  
h[Ndtq>3{  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ }wa}hIqx  
} IIK~d,  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ 6M O|s1zk  
@&!=m]D*  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»